Today: 12 June 2026
RTX Stock Watch: Patriot Missile Work Mounts as U.S. Fast-Tracks $8.6 Billion Arms Sales
2 May 2026
2 mins read

RTX Stock Watch: Patriot Missile Work Mounts as U.S. Fast-Tracks $8.6 Billion Arms Sales

ARLINGTON, Virginia, May 2, 2026, 14:08 EDT

RTX Corporation landed the role of principal contractor for two U.S.-approved arms deals in the Middle East, bringing the aerospace and defense giant back into the spotlight as the U.S. clears fresh missile defense sales for Qatar and Kuwait. The State Department greenlit over $8.6 billion in total sales to Qatar, Kuwait, Israel, and the United Arab Emirates. RTX and Lockheed Martin both appeared on the Qatar Patriot restock and Kuwait’s integrated battle-command system contracts. Northrop Grumman was also tapped for the Kuwait system, while BAE Systems featured on precision-weapon deals.

For RTX stock, timing’s key: missile-defense demand has shifted from a minor factor to a major driver of the company’s defense backlog. Last month, RTX reported Raytheon’s first-quarter sales climbed 10% to $6.95 billion, lifted by stronger volume in land and air defense—think Patriot, GEM-T, and also naval munitions.

Raytheon RTX landed a $441.6 million contract modification from the Army for Patriot GEM-T missiles, according to a U.S. government notice. The GEM-T, which stands for Guidance Enhanced Missile-Tactical, serves as a Patriot interceptor—built to take down incoming aircraft or missiles. The work is set for Chambersburg, Pennsylvania, with delivery slated for Sept. 30, 2026.

Patriot wasn’t the only program seeing movement. Earlier this week, Raytheon secured an $833 million Navy modification—covering Evolved SeaSparrow Missile Block 2 assemblies and containers—for the U.S. plus allied buyers: Australia, Canada, Germany, Norway, Spain, and Türkiye. The contract stretches through September 2030.

RTX Chairman and CEO Chris Calio, following the first-quarter report, pointed to “making significant investments to increase output,” with robust defense demand boosting the company’s expectations for 2026. RTX bumped up its adjusted sales guidance, now projecting $92.5 billion to $93.5 billion, and lifted its adjusted EPS view to a range of $6.70 to $6.90. RTX

The board bumped up RTX’s quarterly dividend by 7.4%, now at 73 cents a share—shareholders of record as of May 22 will see payment on June 11. It’s a modest move compared to the missile announcement, yet the company is managing to put cash back in investors’ hands even as it supports increased production.

There’s a caveat here. While the State Department approval is a step forward, it doesn’t spell out how much revenue RTX stands to gain—or when those contracts might actually materialize. Cost headwinds aren’t letting up either. Following its earnings, RTX’s management pointed out they’ve already paid $500 million in tariffs imposed under the International Emergency Economic Powers Act, legislation that allows for emergency trade actions. They’re considering seeking refunds.

RTX closed Friday at $173.99, slipping $2.08 on the day. Shares swung from $173.34 to $177.07 during the session. The company’s market cap sat around $234.3 billion.

Investors face a straightforward concern: just how fast approved air-defense deals and contract tweaks start hitting the top line, and whether production can ramp without slicing into profit. Right now, headlines tilt toward RTX’s Raytheon. Still, execution risk hasn’t gone anywhere.

Stock Market Today

  • Novo Nordisk Stock Valuation Gap Highlights Investor Debate Post Pullback
    June 12, 2026, 1:44 AM EDT. Novo Nordisk (NYSE:NVO) shares fell 6.5% over the past month and are down 16.1% year-to-date, closing at $43.96. Despite recent weakness, Simply Wall St data reveals a substantial valuation gap, with a fair value estimate near $95 per share, suggesting the stock could be undervalued by over 50%. The fair value reflects expectations of durable franchise strength and expanding product lines amid a competitive market, particularly GLP-1 drug pricing pressure. Investors face a split view between potential upside from growth and risks linked to pricing pressures and margin compression. The stock's recent momentum slowdown contrasts with longer-term returns, prompting calls to assess Novo Nordisk's risk-reward balance amid evolving healthcare AI sector dynamics.

Latest articles

AI Names Drop, Oil Upends Inflation Bets, US Stocks Slip

Dow up 930 points after hours as tech lifts Nasdaq

12 June 2026
Dow soars 929.97 points for its strongest session in months as easing geopolitical risk and a rebound in tech drive ETFs higher after hours; chip stocks surge with the PHLX Semiconductor Index up 7.9%, while Adobe drops 5.44% after CFO exit despite raised forecasts.
Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

12 June 2026
Keel Infrastructure Corp. surged 5.14% to $5.52 after closing $458 million in 1.250% convertible senior notes due 2032, with proceeds aimed at accelerating AI and high-performance computing data center projects; the notes’ initial conversion price is $7.41, about 25% above the June 4 close, while analysts’ 12-month price targets range from $3.00 to $8.00, averaging $5.52.
McDonald’s Corporation Stock Slides Before Q1 Earnings as Value Menu Faces Wall Street Test
Previous Story

McDonald’s Corporation Stock Slides Before Q1 Earnings as Value Menu Faces Wall Street Test

Arista Networks Stock Faces AI Earnings Test After Morgan Stanley Target Boost
Next Story

Arista Networks Stock Faces AI Earnings Test After Morgan Stanley Target Boost

Go toTop